Biogen has reached a settlement and license agreement with Forward Pharma for its best-selling multiple sclerosis drug ahead of the completion of a patent-interference case.
WSJ.com: Health, Wall Street Journal: Business: Health
Tue, 01/17/2017 - 10:38am
Biogen has reached a settlement and license agreement with Forward Pharma for its best-selling multiple sclerosis drug ahead of the completion of a patent-interference case.